Role of Aberrant Striatal Dopamine D1Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine
Authors:
- Francesco NapolitanoFNFrancesco Napolitano
- Alessandra Bonito-OlivaABAlessandra Bonito-Oliva
- Mauro FedericiMFMauro Federici
- Manolo CartaManolo Carta
- Francesco ErricoFrancesco Errico
- Salvatore MagaraSMSalvatore Magara
- Giuseppina MartellaGiuseppina Martella
- Robert NisticòRNRobert Nisticò
- Diego CentonzeDiego Centonze
- Antonio PisaniAntonio Pisani
- Howard H. GuHGHoward H. Gu
- Nicola B. MercuriNMNicola B. Mercuri
Open Access
- 18 August 2010
- journal article
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 30 (33) , 11043-11056
Abstract
Attention deficit/hyperactivity disorder (ADHD) is characterized by inattention, impulsivity, and motor hyperactivity. Several lines of research support a crucial role for the dopamine transporter (DAT) gene in this psychiatric disease. Consistently, the most commonly prescribed medications in ADHD treatment are stimulant drugs, known to preferentially act on DAT. Recently, a knock-in mouse [DAT-cocaine insensitive (DAT-CI)] has been generated carrying a cocaine-insensitive DAT that is functional but with reduced dopamine uptake function. DAT-CI mutants display enhanced striatal extracellular dopamine levels and basal motor hyperactivity. Herein, we showed that DAT-CI animals present higher striatal dopamine turnover, altered basal phosphorylation state of dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP32) at Thr75 residue, but preserved D2receptor (D2R) function. However, although we demonstrated that striatal D1receptor (D1R) is physiologically responsive under basal conditions, its stimulus-induced activation strikingly resulted in paradoxical electrophysiological, behavioral, and biochemical responses. Indeed, in DAT-CI animals, (1) striatal LTP was completely disrupted, (2)R-(+)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 81297) treatment induced paradoxical motor calming effects, and (3) SKF 81297 administration failed to increase cAMP/protein kinase A (PKA)/DARPP32 signaling. Such biochemical alteration selectively affected dopamine D1Rs since haloperidol, by blocking the tonic inhibition of D2R, unmasked a normal activation of striatal adenosine A2Areceptor-mediated cAMP/PKA/DARPP32 cascade in mutants. Most importantly, our studies highlighted that amphetamine, nomifensine, and bupropion, through increased striatal dopaminergic transmission, are able to revert motor hyperactivity of DAT-CI animals. Overall, our results suggest that the paradoxical motor calming effect induced by these drugs in DAT-CI mutants depends on selective aberrant phasic activation of D1R/cAMP/PKA/DARPP32 signaling in response to increased striatal extracellular dopamine levels.Keywords
This publication has 75 references indexed in Scilit:
- Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholineBrain, 2009
- Candidate gene studies of ADHD: a meta-analytic reviewHuman Genetics, 2009
- Getting specialized: presynaptic and postsynaptic dopamine D2 receptorsCurrent Opinion in Pharmacology, 2009
- Dopamine transporter inhibition is required for cocaine-induced stereotypyNeuroReport, 2008
- The binding sites for cocaine and dopamine in the dopamine transporter overlapNature Neuroscience, 2008
- Parallel Loss of Hippocampal LTD and Cognitive Flexibility in a Genetic Model of HyperdopaminergiaNeuropsychopharmacology, 2007
- Brain dopamine transporter levels in treatment and drug naïve adults with ADHDNeuroImage, 2007
- Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporterProceedings of the National Academy of Sciences, 2006
- Attention-Deficit/Hyperactivity Disorder: A Selective OverviewBiological Psychiatry, 2005
- Distribution of adenosine A2 receptor mRNA in the human brainNeuroscience Letters, 1991